search
Back to results

Transcutaneous Vagal Nerve Stimulation: Influence on miRNA, Inflammation, Cerebral Resting State and Gastric Motility (EpimiRNA_D)

Primary Purpose

Epilepsy

Status
Completed
Phase
Phase 1
Locations
Germany
Study Type
Interventional
Intervention
Transcutaneous vagal nerve stimulation
Sponsored by
Philipps University Marburg Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Epilepsy focused on measuring Vagus Nerve Stimulation

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Age between 18 and 65 years
  • Written informed consent

Exclusion Criteria:

  • pregnancy
  • active implants (like cardiac pacemaker, cochlea implant, implanted VNS)
  • contraindications for MRI (e. g. metal fragments, claustrophobia)
  • skin lesions in the ara of the left ear conch
  • nickel allergy
  • drug or alcohol abuse
  • current acute disease or medical history of chronic disease
  • participant is under legal guardianship

Sites / Locations

  • Philipps-University Marburg, Dept. of Neurology, Epilepsy Center Hesse-Marburg

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Sham Comparator

Arm Label

tVNS

Sham-tVNS

Arm Description

Transcutaneous vagal nerve stimulation with 25 Hz

Sham transcutaneous vagal nerve stimulation with 1 Hz

Outcomes

Primary Outcome Measures

miRNA expression profile in plasma of healthy persons before and after tVNS as compared to before and after sham tVNS

Secondary Outcome Measures

Serum concentrations of different cytokines, chemokines and neuropeptides in healthy persons before and after tVNS as compared to before and after sham tVNS
Differences in cerebral microstructural (DTI-MRI) and functional (resting state network, fMR) between tVNS group and control group
Differences in gastric motility between tVNS group and control group

Full Information

First Posted
February 4, 2015
Last Updated
September 12, 2018
Sponsor
Philipps University Marburg Medical Center
Collaborators
European Commission
search

1. Study Identification

Unique Protocol Identification Number
NCT02359188
Brief Title
Transcutaneous Vagal Nerve Stimulation: Influence on miRNA, Inflammation, Cerebral Resting State and Gastric Motility
Acronym
EpimiRNA_D
Official Title
Influence of Transcutaneous Vagal Nerve Stimulation on Expression of microRNA, Cytokines, Chemokines and Neuropeptides as Well as Cerebral Resting State and Gastric Motility
Study Type
Interventional

2. Study Status

Record Verification Date
September 2018
Overall Recruitment Status
Completed
Study Start Date
August 2016 (undefined)
Primary Completion Date
August 2018 (Actual)
Study Completion Date
August 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Philipps University Marburg Medical Center
Collaborators
European Commission

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Randomized, double-blind trial to investigate the influence of a single 4 hours episode of transcutaneous vagal nerve stimulation on the expression of microRNA, various cytokines, chemokines, neuropeptides, cerebral resting state and gastric motility in healthy volunteers.
Detailed Description
Transcutaneous vagal nerve stimulation (tVNS) is a non-invasive treatment option for epilepsy. TVNS works via electrical stimulation of the vagal nerve in the outer ear area via two steel electrodes and is performed for about 4 hours per day. Its mechanism of action is unknown. We hypothesize that expression of microRNA (miRNA), and/or release of cytokines, chemokines or neuropeptides is involved in the anticonvulsant activity. TVNS might also influence the cerebral resting state as measured by functional magnetic resonance imaging (fMRI). Due to it's anatomical connections, stimulation of the vagal nerve may furthermore result in altered gastric motility. This study aims to detect levels of miRNA, cytokines, chemokines and neuropeptides in the blood of healthy volunteers before and after 4 hours of conventional tVNS or sham tVNS. Cerebral resting state and gastric motility will be measured by fMRI. To this end, 60 healthy volunteers will be recruited and divided into 2 groups. 30 healthy volunteers will be treated with tVNS (25 Hz) for 4 hours (tVNS group). 30 healthy volunteers will be treated with sham tVNS (1 Hz) for 4 hours (control group). On day 1 of the study, participants will be randomized to one of the two groups. Blood will be drawn from all participants at baseline. Both groups receive a standardized breakfast. TVNS ear electrodes will be put into place for 4 hours without electrical stimulation. Thereafter, blood will be drawn. On day 2 of the study, blood will be drawn, and all participants receive a standardized breakfast again. Afterwards, tVNS (25 Hz) will be performed in participants of the tVNS group, and sham tVNS (1 Hz) will be performed in participants of the control group. TVNS or sham tVNS end after 4 hours. Blood will be drawn immediately after stimulation end. Thereafter, MRI will be performed in all participants (fMRT resting state, gastric motility). This ends the study for the participant.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Epilepsy
Keywords
Vagus Nerve Stimulation

7. Study Design

Primary Purpose
Basic Science
Study Phase
Phase 1, Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
60 (Actual)

8. Arms, Groups, and Interventions

Arm Title
tVNS
Arm Type
Active Comparator
Arm Description
Transcutaneous vagal nerve stimulation with 25 Hz
Arm Title
Sham-tVNS
Arm Type
Sham Comparator
Arm Description
Sham transcutaneous vagal nerve stimulation with 1 Hz
Intervention Type
Device
Intervention Name(s)
Transcutaneous vagal nerve stimulation
Other Intervention Name(s)
NEMOS tVNS device
Intervention Description
4 hours of transcutaneous vagal nerve stimulation
Primary Outcome Measure Information:
Title
miRNA expression profile in plasma of healthy persons before and after tVNS as compared to before and after sham tVNS
Time Frame
After 4 hours of VNS
Secondary Outcome Measure Information:
Title
Serum concentrations of different cytokines, chemokines and neuropeptides in healthy persons before and after tVNS as compared to before and after sham tVNS
Time Frame
After 4 hours of VNS
Title
Differences in cerebral microstructural (DTI-MRI) and functional (resting state network, fMR) between tVNS group and control group
Time Frame
After 4 hours of VNS
Title
Differences in gastric motility between tVNS group and control group
Time Frame
After 4 hours of VNS

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Age between 18 and 65 years Written informed consent Exclusion Criteria: pregnancy active implants (like cardiac pacemaker, cochlea implant, implanted VNS) contraindications for MRI (e. g. metal fragments, claustrophobia) skin lesions in the ara of the left ear conch nickel allergy drug or alcohol abuse current acute disease or medical history of chronic disease participant is under legal guardianship
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Sebastian Bauer, Dr.
Organizational Affiliation
Philipps-University Marburg, Dept. of Neurology
Official's Role
Principal Investigator
Facility Information:
Facility Name
Philipps-University Marburg, Dept. of Neurology, Epilepsy Center Hesse-Marburg
City
Marburg
State/Province
Hesse
ZIP/Postal Code
35043
Country
Germany

12. IPD Sharing Statement

Learn more about this trial

Transcutaneous Vagal Nerve Stimulation: Influence on miRNA, Inflammation, Cerebral Resting State and Gastric Motility

We'll reach out to this number within 24 hrs